| abstract |
The present invention relates to compounds of the formula in which: R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6 cycloalkyl, -CH2-cycloalkyl C3-6, -O-CH2-C3-6 cycloalkyl, -O- (CH2) 2-O-lower alkyl, S (O) 2CH3, SF5, -C (O) NH-lower alkyl, phenyl, -O- pyrimidinyl, optionally substituted by lower alkoxy substituted by halogen or is benzyl, oxetanyl or furanyl; m is number 1 or 2; Ar is aryl or heteroaryl, selected from the group consisting of phenyl, naphthyl, pyrimidinyl, pyridinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo [d] [1.3] dioxolyl, 5,6,7,8-tetrahydro-quinazolinyl, pyrazolyl, pyrazinyl, pyridazinyl and 1,3,4-oxadiazolyl; Y is a bond, -CH2-, -CH2CH2-, -CH (CF3) - or -CH (CH3) -; R2 is hydrogen or lower alkyl; A is CR or N; and R is hydrogen, cyano, halogen or lower alkyl; R 'is hydrogen or halogen; with the proviso that if R 'is halogen, then A is CH; B is CH or N; n is the number 0, 1 or 2; X is a bond, -CH2- or -O-; or the pharmaceutically active acid addition salts thereof. It has now been found that the compounds of the formula I have good affinity with the receptors associated with trace amines (TAARs), especially with TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, for example schizophrenia, neurological diseases, for example Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy , migraine, hypertension, substance abuse and metabolic disorders, for example food ingestion disorders, diabetes, diabetic complications, obesity, dyslipidemia, consumption disorders and energy assimilation, disorders and malfunction of body temperature, homeostasis, sleep disorders and circadian rhythm and disorders cardiovascular |